Evidence map›Paper›PMID 19389921›Full record

ArticleMolecular pharmacology2009

Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation.

Qisheng Liu, Mark S Bee, Agnes Schonbrunn

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 36 citations in OpenAlex.

  1. The LPAInternational journal of molecular sciences · 2021
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Pituitary somatostatin receptor signaling.Trends in endocrinology and metabolism: TEM · 2010
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Qisheng LiuDepartment of Integrative Biology and Pharmacology, University of Texas-Houston, School of Medicine, Houston, TX 77225, USA.
Mark S Bee
Agnes Schonbrunn
The University of Texas at Austin · US

Funding

SOMATOSTATIN RECEPTOR STRUCTURE AND FUNCTIONR01DK032234 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SCHONBRUNN, AGNES · 1987 to 2010
$3.2M
Regulation of somatostatin receptor signalingR56DK032234 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SCHONBRUNN, AGNES · 2012 to 2012
$114k
NIDDK NIH HHS DK032234NIDDK NIH HHS R01 DK032234
6 · The paper itself

Abstract

Somatostatin receptor subtype 2A (sst2A) mediates many of the endocrine and neuronal actions of somatostatin and is the target of somatostatin analogs in cancer therapy. As with many G-protein-coupled receptors, agonist stimulation causes sst2A receptor desensitization and internalization, events that require receptor phosphorylation. Furthermore, heterologous receptor activation of protein kinase C (PKC) also increases sst2A receptor phosphorylation and internalization. Here we analyzed a series of sst2A receptor mutants biochemically to identify residues in the receptor carboxyl terminus that were phosphorylated upon agonist stimulation, and we then generated four phosphorylation-sensitive antibodies to those residues. Once the selectivity of each antibody for its phosphorylated and nonphosphorylated target sequence was determined, the phospho-site-specific antibodies were used to demonstrate that somatostatin treatment of Chinese hamster ovary (CHO) cells expressing the wild type sst2A receptor increased phosphorylation on five residues in the receptor C terminus: Ser341, Ser343, Ser348, Thr353, and Thr354. Phorbol 12-myristate 13-acetate (PMA) increased receptor phosphorylation only on Ser343. Inhibition of PKC blocked PMA but not somatostatin stimulation, showing that different kinases catalyzed Ser343 phosphorylation. In contrast, somatostatin-stimulated sst2A receptor phosphorylation was inhibited by knockdown of G-protein coupled receptor kinase-2 with siRNA. Somatostatin increased sst2A receptor phosphorylation on the same five residues in GH4C1 pituitary cells as in CHO cells. However, PMA stimulated sst2A receptor phosphorylation on both Ser343 and Ser348 in GH4C1 cells. These results characterize the complex pattern of sst2A receptor phosphorylation by agonist and second messenger-activated kinases for the first time and indicate that cell type-specific regulation of sst2A receptor phosphorylation occurs.

Indexed as

AnimalsCHO CellsColforsinCricetinaeCricetulusCyclic AMP-Dependent Protein KinasesEnzyme-Linked Immunosorbent AssayG-Protein-Coupled Receptor Kinase 2HumansPhosphorylationProtein Kinase CReceptors, SomatostatinStructure-Activity RelationshipTetradecanoylphorbol AcetateColforsinCyclic AMP-Dependent Protein KinasesG-Protein-Coupled Receptor Kinase 2GRK2 protein, humanProtein Kinase CReceptors, Somatostatinsomatostatin receptor sst2ATetradecanoylphorbol Acetate

Identifiers

PMID19389921
PMCPMC2701454
OpenAlexW2068857097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.